Exposure to lead (Pb) and cadmium (Cd) poses risk to human health. It is known that
these metals have toxic impact on male reproductive system, leading to physiological
disorders and infertility. Limited data indicates the carcinogenic potential of Pb, while Cd has
been recognized as carcinogen. Benchmark dose-effect modeling can be applied to data from
human, animal and ecotoxicological studies with the aim to obtain Benchmark dose (BMD),
starting point in human health risk assessment. The aim of this study was to use Benchmark
modeling to determine the dose-effect relationship between Pb and Cd levels in tissues of
testicular and prostate cancer patients and serum testosterone levels. The study was
conducted at the Clinical Center of Serbia, and included 104 patients with prostate and
testicular cancer. Cd and Pb levels (ng/g) were measured by atomic absorption
spectrophotometry in isolated healthy surrounding and carcinoma-affected tissues.
Testosterone levels (ng/mL) were measured using the chemiluminescence immunoassay
(CLIA) method. Dose-effect modeling was performed using PROAST70.1 software with
continuous data. The dose dependence was obtained between Cd levels in tumor tissue and
testosterone levels (BMD: 0.0024 ng Cd/g, prostate cancer and 0.0038 ng Cd/g, testicular
cancer). Dose dependence was obtained between Cd levels in healthy surrounding tissue and
testosterone levels (BMD: 0.0092 ng Cd/g). No dose dependence was obtained when
modeling Pb levels as a dose. The data from this study indicate a potential link between Cd
and testosterone levels, i.e. potential association of Cd exposure with male reproductive
health.Izloženost olovu (Pb) i kadmijumu (Cd) predstavlja rizik po zdravlje ljudi. Poznato je da ovi
metali deluju toksično na muški reproduktivni sistem dovodeći do poremećaja fizioloških
funkcija i neplodnosti. Ograničen broj studija ukazuje na kancerogeni potencijal Pb, dok je Cd
poznatihumani karcinogen. Benchmark modelovanje odnosa doza-efekat se teoretski može
primeniti na podacima iz humanih, animalnih i ekotoksikoloških studija, sa ciljem dobijanja
Benchmark doze (BMD) kao polazne tačke u proceni rizika po zdravlje ljudi. Cilj ovog rada
bio je da se Benchmark modelovanjem utvrdi odnos doza-efekat između nivoa Pb i Cd u
tkivima karcinoma testisa i prostate pacijenata i nivoa testosterona u serumu. Studija je
sprovedena na Kliničkom centru Srbije i uključila je 104 pacijenta sa karcinomom prostate i
testisa. Nivoi Cd i Pb (ng/g) su izmereni metodom atomske apsorpcione spektrofotometrije u
izolovanim zdravim okolonim i karcinomom zahvaćenim tkivima. Nivoi testosterona
(ng/mL) su mereni pomoću metode direktnog kompetitivnog hemiluminiscentnog
imunoeseja (CLIA). Modelovanje odnosa doza-efekat je vršeno pomoću PROAST 70.1
softvera (RIVM, Holandija) uz upotrebu kontinuiranih podataka. Dozna zavisnost je dobijena
između nivoa Cd u tumorskom tkivu i nivoa testosterona gde je BMD vrednost iznosila
0,0024 ng Cd/g (karcinom prostate) i 0,0038 ng Cd/g (karcinom testisa). Dozna zavisnost je
dobijena i za modelovanje odnosa nivoa Cd u zdravom tkivu i testosterona, sa BMD
vrednošću 0,0092 ng Cd/g. Pri modelovanju nivoa Pb nije dobijena dozna zavisnost. Podaci
ove studije ukazuju na potencijalnu vezu između nivoa Cd u tkivu i nivoa testosterona,
ukazujući na efekte izloženosti ovom metalu na muško reproduktivno zdravlje.VIII Kongres farmaceuta Srbije sa međunarodnim učešćem, 12-15.10.2022. Beogra
